TY - JOUR
T1 - Targeting chronic inflammation as a potential adjuvant therapy for osteoporosis
AU - Livshits, Gregory
AU - Kalinkovich, Alexander
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Systemic, chronic, low-grade inflammation (SCLGI) underlies the pathogenesis of various widespread diseases. It is often associated with bone loss, thus connecting chronic inflammation to the pathogenesis of osteoporosis. In postmenopausal women, osteoporosis is accompanied by SCLGI development, likely owing to estrogen deficiency. We propose that SCGLI persistence in osteoporosis results from failed inflammation resolution, which is mainly mediated by specialized, pro-resolving mediators (SPMs). In corroboration, SPMs demonstrate encouraging therapeutic effects in various preclinical models of inflammatory disorders, including bone pathology. Since numerous data implicate gut dysbiosis in osteoporosis-associated chronic inflammation, restoring balanced microbiota by supplementing probiotics and prebiotics could contribute to the efficient resolution of SCGLI. In the present review, we provide evidence for this hypothesis and argue that efficient SCGLI resolution may serve as a novel approach for treating osteoporosis, complementary to traditional anti-osteoporotic medications.
AB - Systemic, chronic, low-grade inflammation (SCLGI) underlies the pathogenesis of various widespread diseases. It is often associated with bone loss, thus connecting chronic inflammation to the pathogenesis of osteoporosis. In postmenopausal women, osteoporosis is accompanied by SCLGI development, likely owing to estrogen deficiency. We propose that SCGLI persistence in osteoporosis results from failed inflammation resolution, which is mainly mediated by specialized, pro-resolving mediators (SPMs). In corroboration, SPMs demonstrate encouraging therapeutic effects in various preclinical models of inflammatory disorders, including bone pathology. Since numerous data implicate gut dysbiosis in osteoporosis-associated chronic inflammation, restoring balanced microbiota by supplementing probiotics and prebiotics could contribute to the efficient resolution of SCGLI. In the present review, we provide evidence for this hypothesis and argue that efficient SCGLI resolution may serve as a novel approach for treating osteoporosis, complementary to traditional anti-osteoporotic medications.
KW - Chronic inflammation
KW - Gut dysbiosis
KW - Osteoporosis
KW - Specialized pro-resolving mediators
UR - http://www.scopus.com/inward/record.url?scp=85135123621&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2022.120847
DO - 10.1016/j.lfs.2022.120847
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35908619
AN - SCOPUS:85135123621
SN - 0024-3205
VL - 306
JO - Life Sciences
JF - Life Sciences
M1 - 120847
ER -